Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy

NCT ID: NCT00503568

Last Updated: 2016-12-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-05-31
• Study Completion Date: 2012-08-31

Brief Summary

RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells.

PURPOSE: This phase I trial is studying the effects of gp96-Ig vaccine therapy in treating patients with stage III, stage IV, or relapsed non-small cell lung cancer treated with first-line chemotherapy.

Detailed Description

Overall Goals:

• to evaluate the safety and induction of anti-tumor immunity by administration of an immunogenic human tumor cell vaccine, and assess immune response in relation to clinical outcome.

Primary Aim:

• to evaluate the safety of administering a heat shock protein gp96-Ig-secreting allogeneic tumor cell-vaccine (gp96-Ig vaccine) in patients with advanced NSCLC.

Secondary Aims:

• to study the immune response to vaccination,
• to monitor clinical responses and
• to recommend a dose-schedule combination for further testing in an initial Phase II trial of vaccine efficacy.

Conditions

Lung Cancer

Keywords

stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; recurrent non-small cell lung cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

DS-1: gp96-ig Dose Schedule 1

Dose Schedule 1 (DS-1): Ad100-gp96Ig-HLA A1 Vaccine 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient;

Group Type: EXPERIMENTAL

Ad100-gp96Ig-HLA A1

Intervention Type: BIOLOGICAL

Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient

DS-2: gp96-ig Dose Schedule 3

Dose Schedule 2 (DS-2): Ad100-gp96Ig-HLA A1 Vaccine 2X10\^7 cells weekly, maximum 18 vaccines/patient;

Group Type: EXPERIMENTAL

Ad100-gp96Ig-HLA A1

Intervention Type: BIOLOGICAL

Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient

DS-3: gp96-ig Dose Schedule 3

Dose Schedule 3 (DS-3): Ad100-gp96Ig-HLA A1 Vaccine 1x10\^7 cells twice weekly, maximum 36 vaccines/patient

Group Type: EXPERIMENTAL

Ad100-gp96Ig-HLA A1

Intervention Type: BIOLOGICAL

Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient

Interventions

Ad100-gp96Ig-HLA A1

Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient

Intervention Type: BIOLOGICAL

Other Intervention Names

gp96-vaccine; gp96-Ig and HLA A1 transfected Non-Small Cell Lung Cancer cell line

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed NSCLC (squamous, adeno-, large cell anaplastic, bronchoalveolar, and non-small cell carcinoma NOS): stage IIIB with malignant pleural effusion, stage IV, or recurrent disease.
• At least one site of bi-dimensionally measurable disease.
• Metastasis if present and treated must be stable by CT scan or MRI for at least 8 weeks.
• Patient must have received and failed at least one line of chemotherapy.
• Age >= 18 years.
• ECOG performance status 0-2.
• Life expectancy >= 3 months.
• Laboratory parameters:

• Hemoglobin levels >= 10.0 (transfusions allowed if necessary).
• ANC >= 1,500.
• Platelets >= 100k.
• Creatinine clearance >= 50 ml/min.
• Total and direct bilirubin: < 2.5 X upper institution limit for normal.
• Liver function tests: AST, ALT, and AlkP < 2.5 X upper institution limit for normal.
• Signed informed consent.
• Autopsy consent - although not a requirement for study entry, patients who consent to participate in study will be made aware of the critical importance of a post-mortem examination in the event of the patient's death after receiving therapy with this experimental vaccine. Therefore, pre-treatment written agreement to autopsy will be sought from the patient, or verbal agreement to autopsy will be sought in the presence of the next of kin or other family members.

Exclusion Criteria

• Active or symptomatic cardiac disease such as congestive heart failure, angina pectoris or recent myocardial infarction. Patients with history of these conditions who are stable taking cardiac medications will also be excluded.
• Pregnant or lactating women (negative test for pregnancy is required of women of childbearing potential).
• Known HIV infection.
• Uncontrolled or untreated brain or spinal cord metastases.
• Active infection.
• Concomitant steroid or other immunosuppressive therapy.
• Other active malignancies present within the past three years, except for basal and/or squamous cell carcinoma(s) or in situ cervical cancer.
• Alcohol or chemical abuse.
• Meningeal carcinomatosis.
• Chemotherapy, radiation therapy, or other anti-tumor therapy during the last four weeks.
• Prior biologic response modifier therapy.
• Refusal in fertile men or women to use effective birth control measures during and for six months after the completion of treatment on study.
• Immune deficiency syndromes, including the following: rheumatoid arthritis, systemic lupus erythematosus, Sjogren's disease, sarcoidosis, vasculitis, polymyositis, glomerulonephritis.
• Compromised lung function:

• FeV1 < 30% of the predicted value, or
• DLCO < 30% of the predicted value, or
• PCO2 > 45 mmHg.
• Any patient enrolled on study whose respiratory symptoms have experienced marked deterioration not related to a known cause, such as pneumonia, congestive heart failure, or pulmonary embolism, will have a repeat PFT evaluation, and if the above parameter values for FeV1, DLCO, or PCO2 are seen, will be excluded from further treatment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Miami

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Luis E. Raez, MD, FACP

Role: STUDY_CHAIR

University of Miami Sylvester Comprehensive Cancer Center

Locations

University of Miami Sylvester Comprehensive Cancer Center

Miami, Florida, United States

Countries

United States

References

Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004 Jul 15;22(14):2800-7. doi: 10.1200/JCO.2004.10.197.

Reference Type: BACKGROUND

PMID: 15254047 (View on PubMed)

Raez LE, Podack ER, CD8 T cell response in a phase I study of therapeutic vaccination of advanced NSCLC with allogeneic tumor cells secreting endoplasmic reticulum-chaperone gp96-Ig-peptide complexes. Advances in Lung Cancer 2(1): 9-18, 2013 doi:10.4236/alc.2013.21002

Reference Type: RESULT

Other Identifiers

SCCC-2002041

Identifier Type: OTHER

Identifier Source: secondary_id

WIRB-20050969

Identifier Type: OTHER

Identifier Source: secondary_id

20020225

Identifier Type: -

Identifier Source: org_study_id

NCT00247065

Identifier Type: -

Identifier Source: nct_alias